文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

耐利福平结核二线注射药物:已知的魔鬼是否更好?

Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

WHO 2020指南推荐耐利福平结核(RR-TB)全口服氟喹诺酮类方案,以贝达喹啉替代二线注射药物(SLID)。三个队列数据显示获得性贝达喹啉耐药率为2.5%至30.8%,多数情况下SLID未能提供保护。作者呼吁在证据明确前更谨慎使用有限强效二线抗结核药物。

要点

  • 获得性贝达喹啉耐药率在三个队列中为2.5%至30.8%
  • 多数情况下SLID未能防止贝达喹啉耐药
  • SLID从第1天起改为每周三次可大幅避免严重耳毒性

核心结论

  • 在获得性耐药预防活性证据明确前,应更谨慎使用有限的强效二线抗结核药物。
  • 若贝达喹啉耐药如此易获得,将无法保护氟喹诺酮类和其他药物免于耐药。

研究设计与样本

  • 本文为述评,基于三个队列数据及WHO 2020指南进行讨论。

主要发现

  • 三个队列显示获得性贝达喹啉耐药率介于2.5%与30.8%之间。
  • 多数情况下SLID未能提供防止贝达喹啉耐药获得的保护。

关键数值与推荐

  • WHO 2020指南推荐RR-TB全口服氟喹诺酮类方案,以贝达喹啉替代SLID。
  • SLID从第1天起改为每周三次给药,且治疗前或治疗中出现任何程度听力异常即替换SLID,可大幅避免严重耳毒性。

临床怎么用

  • 对RR-TB患者使用贝达喹啉时需关注获得性耐药风险。
  • SLID可从第1天起采用每周三次给药以减少耳毒性。
  • 治疗前及治疗中听力异常时应替换SLID。

局限性

  • 证据来自三个队列,非随机对照试验。
  • 原文未报告队列样本量、置信区间及P值等详细统计量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In its 2020 guidelines for the treatment of rifampicin-resistant TB (RR-TB), the WHO recommends all-oral fluoroquinolone-based regimens, with bedaquiline replacing the second-line injectable drugs (SLIDs). SLIDs were used for their strong acquired resistance-preventing activity. Data from three cohorts showed acquired bedaquiline resistance ranging between 2.5% and 30.8%, with no protection from a SLID in most cases. If bedaquiline resistance is that easily acquired, it will fail to protect fluoroquinolones and other drugs from acquiring resistance. Until evidence on resistance-preventing activity shows that SLIDs can safely be replaced, we call for more prudent use of the few potent second-line TB drugs available. Studies on new treatment regimens need to prioritize the prevention of acquired resistance along with treatment success. Meanwhile, reducing the dosing of SLIDs to thrice weekly from Day 1, and their replacement for any degree of audiometry abnormalities before or during treatment will largely avoid serious ototoxicity.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Tahseen S, Van Deun A, de Jong BC, et al. Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know? J Antimicrob Chemother. 2021. PMID: 33258921. doi:10.1093/jac/dkaa489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。